Trade

with

AcelRx Pharmaceuticals Inc
(NASDAQ: ACRX)
AdChoices
6.78
+0.13
+1.95%
After Hours :
6.78
0.00
0.00%

Open

6.69

Previous Close

6.65

Volume (Avg)

237.43k (1.05M)

Day's Range

6.59-6.83

52Wk Range

5.22-13.64

Market Cap.

294.10M

Dividend Rate ( Yield )

-

Beta

2.16

Shares Outstanding

43.38M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Devices
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 29.50M

    • Net Income

    • -23.43M

    • Market Cap.

    • 294.10M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -47.40

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.16

    • Forward P/E

    • -5.73

    • Price/Sales

    • 10.30

    • Price/Book Value

    • 5.29

    • Price/Cash flow

    • -222.22

      • EBITDA

      • -21.32M

      • Return on Capital %

      • -19.02

      • Return on Equity %

      • -43.59

      • Return on Assets %

      • -19.02

      • Book Value/Share

      • 1.28

      • Shares Outstanding

      • 43.38M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 8.67

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -1.45

        • Cashflow Estimate

        • 0.33

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -82.60

          • 2.66

          • Net Income

            YTD/YTD (last year)

          • -

          • -22.64

          • Net Income

            Q/Q (last year)

          • -

          • -29.83

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 4.60

          • Net Income

            5-Year Annual Average

          • -

          • -1.34

          • Dividends

            5-Year Annual Average

          • -

          • -0.25

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.08

            • Pre-Tax Margin

            • -47.40

            • 15.19

            • Net Profit Margin

            • -47.40

            • 13.09

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 65.03

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 17.99

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 191.75B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.40

              • 0.34

              • Current Ratio

              • 10.67

              • 2.55

              • Quick Ratio

              • 10.57

              • 1.83

              • Interest Coverage

              • -7.07

              • 11.70

              • Leverage Ratio

              • 1.81

              • 1.86

              • Book Value/Share

              • 1.28

              • 11.67

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -21.83

                • 35.09

                • P/E Ratio 5-Year High

                • -43.47

                • 224.03

                • P/E Ratio 5-Year Low

                • -5.61

                • 60.23

                • Price/Sales Ratio

                • 10.41

                • 3.24

                • Price/Book Value

                • 5.35

                • 3.29

                • Price/Cash Flow Ratio

                • -222.22

                • 19.05

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -43.59

                    (-)

                  • 12.33

                    (18.16)

                  • Return on Assets %

                    (5-Year Average)

                  • -19.02

                    (-83.50)

                  • 6.62

                    (8.69)

                  • Return on Capital %

                    (5-Year Average)

                  • -23.85

                    (-)

                  • 8.49

                    (11.48)

                  • Income/Employee

                  • -

                  • 34.11k

                  • Inventory Turnover

                  • -

                  • 2.77

                  • Asset Turnover

                  • 0.40

                  • 0.51

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -6.67M
                  Operating Margin
                  -22.60
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -222.22
                  Ownership

                  Institutional Ownership

                  85.75%

                  Top 10 Institutions

                  62.07%

                  Mutual Fund Ownership

                  15.66%

                  Float

                  61.58%

                  5% / Insider Ownership

                  2.31%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    610,629

                  • 0.00

                  • 1.41

                  • iShares Nasdaq Biotechnology

                  •  

                    561,152

                  • -0.47

                  • 1.57

                  • Vanguard Total Stock Mkt Idx

                  •  

                    453,032

                  • 0.00

                  • 1.04

                  • Vanguard VIF Small Comp Gr

                  •  

                    450,030

                  • 0.00

                  • 1.04

                  • Oppenheimer Main Street Small Cap VA

                  •  

                    389,860

                  • 0.00

                  • 0.90

                  • iShares Russell 2000 (AU)

                  •  

                    374,061

                  • -1.46

                  • 1.04

                  • Vanguard US Discoveries Fund

                  •  

                    266,105

                  • -5.37

                  • 0.61

                  • Vanguard Extended Market Index Fund

                  •  

                    243,054

                  • 22.72

                  • 0.56

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Perceptive Advisors LLC

                  •  

                    6,574,060

                  • 0.00%

                  • 15.16

                  • Three Arch Management IV LLC

                  •  

                    5,839,722

                  • +44.32%

                  • 13.48

                  • Three Arch Management III LLC

                  •  

                    3,527,319

                  • -9.65%

                  • 8.14

                  • Skyline Venture Management IV LLC

                  •  

                    2,851,933

                  • -31.64%

                  • 6.58

                  • Granahan Investment Management Inc..

                  •  

                    1,559,623

                  • +74.84%

                  • 3.60

                  • BlackRock Fund Advisors

                  •  

                    1,115,876

                  • -5.05%

                  • 2.57

                  • Driehaus Capital Management LLC

                  •  

                    1,115,183

                  • -39.08%

                  • 2.57

                  • Franklin Advisers, Inc.

                  •  

                    964,800

                  • 0.00%

                  • 2.22

                  • Foresite Capital Management I, LLC

                  •  

                    847,983

                  • -38.51%

                  • 1.96

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Devices

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialt...morey pharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. The Company’s main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe ...moreand Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.lessless

                  Key People

                  Mr. Richard A. King

                  CEO/Director/President

                  Mr. Adrian Adams

                  Director/Chairman of the Board

                  Dr. Pamela P. Palmer

                  Chief Medical Officer/Co-Founder/Director

                  Timothy E. Morris

                  CFO/Chief Accounting Officer

                  Mark A. Wan

                  Director

                  • AcelRx Pharmaceuticals Inc

                  • 351 Galveston Drive

                  • Redwood City, CA 94063

                  • USA.Map

                  • Phone: +1 650 216-3500

                  • Fax: +1 650 216-6500

                  • acelrx.com

                  Incorporated

                  2005

                  Employees

                  44

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: